

1 **Title**

2 Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus  
3 vaccine following vaccination campaigns

4 Katharine S. Walter<sup>1\*</sup>, Jonathan Altamirano<sup>2</sup>, ChunHong Huang<sup>3</sup>, Yuan J. Carrington<sup>3</sup>, Frank  
5 Zhou<sup>3</sup>, Jason R. Andrews<sup>4</sup>, Yvonne Maldonado<sup>3,4</sup>

6 1. Division of Epidemiology, University of Utah, Salt Lake City, UT 84105, USA

7 2. Department of Epidemiology and Population Health, Stanford University School of  
8 Medicine, Stanford, CA 94305, USA

9 3. Department of Pediatrics, Stanford University School of Medicine, Stanford, CA,  
10 USA

11 4. Division of Infectious Diseases and Geographic Medicine, Stanford University  
12 School of Medicine, Stanford, CA 94305, USA

13 \*Corresponding Author

14 **Email:** Katharine.Walter@hsc.utah.edu

15 **Author Contributions:** YM, JRA, and KSW designed the study. JA, CH, YC, and FZ  
16 conducted DNA extractions, sample preparation, Sanger sequencing, and data management. KW  
17 performed data analysis and drafted the paper. YM and JRA reviewed the paper and supervised  
18 the project.

19 **Competing Interest Statement:** All authors declare no competing interests.

20 **Classification:** epidemiology, poliovirus

21 **Keywords:** poliovirus, vaccines, virus evolution, transmission, environmental surveillance

22

23

24 **Abstract**

25

26         There is an increasing burden of circulating vaccine-derived polioviruses (cVDPVs) due  
27 to the continued use of oral poliovirus vaccine (OPV). However, the informativeness of routine  
28 OPV VP1 sequencing for the early identification of viruses carrying virulence-associated  
29 reversion mutations has not been directly evaluated in a controlled setting. We prospectively  
30 collected 15,331 stool samples to track OPV shedding from vaccinated children and their  
31 contacts for ten weeks following an immunization campaign in Veracruz State, Mexico and  
32 sequenced VP1 genes from 358 samples. We found that OPV was genetically unstable and  
33 evolves at an approximately clocklike rate that varies across serotypes and by vaccination status.  
34 Alarming, 28% (13/47) of OPV-1, 12% (14/117) OPV-2, and 91% (157/173) OPV-3 of Sabin-  
35 like viruses had  $\geq 1$  known reversion mutation. Our results suggest that current definitions of  
36 cVDPVs may exclude circulating virulent viruses that pose a public health risk and underscore  
37 the need for intensive surveillance following OPV use.

38

39 **Introduction**

40         The global use of oral poliovirus vaccine (OPV), a live, attenuated virus, has been  
41 essential in reducing the burden of poliomyelitis caused by wild poliovirus by 99.9% since  
42 1988<sup>1,2</sup>. The vaccine covers all three wild poliovirus serotypes, is inexpensive, easy to deliver,  
43 and—because it is a live virus—is transmissible from vaccinated children onwards, extending  
44 the reach of vaccination campaigns. However, OPV vaccination is risky—the vaccine virus is  
45 genetically unstable and continues to evolve in vaccinated individuals and their contacts. If OPV  
46 mutates at positions responsible for attenuation of the vaccine virus, it can regain virulence. OPV

47 can regain virulence within a vaccinated individual, causing vaccine-associated paralytic  
48 poliomyelitis, though rarely<sup>3</sup>. OPV may also revert to virulence over transmission chains,  
49 generating outbreaks of circulating vaccine derived polioviruses (cVDPVs).

50 To reduce the risks of cVDPVs, in May 2016, trivalent OPV vaccines (containing  
51 serotypes 1, 2, and 3) were replaced with a bivalent OPV (containing serotypes 1 and 3),  
52 following World Health Organization recommendations. The WHO recommended that routine  
53 immunization with at least one dose of inactivated poliovirus vaccine (IPV) prior to the switch to  
54 bivalent OPV, to increase protection against paralytic disease<sup>4</sup>. However, access to IPV was  
55 limited, leaving large populations of children immunologically naïve to poliovirus type 2. Since  
56 the global switch to bivalent OPV, the majority of paralytic poliovirus cases are now caused by  
57 cVDPVs, not wild poliovirus, the majority of which are serotype 2 viruses (cVDPV2). From  
58 2016 to 2022, type 2 cVDPVs emerged 68 times in 34 countries, leading to more than 1500 cases  
59 of paralytic polio<sup>5</sup> (Fig. 1).

60 The current public health response to outbreaks of cVDPV type 2 is vaccination with  
61 monovalent OPV-2 (mOPV-2), to increase population-level immunity and reduce transmission  
62 risk. However, the outbreak response itself is risky, as mOPV-2 use can generate new cVDPV  
63 outbreaks.

64 Outbreak responses are guided by routine testing of cases of acute flaccid paralysis in  
65 children less 15 and environmental surveillance in more than 30 high-risk countries and  
66 sequencing of the poliovirus VP1 gene<sup>6</sup>. The Global Polio Eradication Initiative (GPEI) defines  
67 VDPVs by their divergence from OPV in the VP1 gene<sup>6</sup>. cVDPVs are defined by evidence of  
68 VDPV transmission, through genetically linked viruses from individuals with acute flaccid  
69 paralysis or environmental samples<sup>6</sup> and assigned to new or existing genetic clusters<sup>7,8</sup>. The

70 identification of new cVDPVs results in an epidemiological investigation and an immunization  
71 response<sup>6</sup>.

72 Previous genomic studies of type 2 cVDPVs and OPV-2 shedding in vaccinated children  
73 and contacts have identified strong within-host selection and tight transmission bottlenecks that  
74 govern the early evolution of type 2 viruses away from the Sabin vaccine strain along a  
75 predictable pathway to virulence<sup>11,12</sup>. Yet previous studies have not yet integrated detailed  
76 molecular and epidemiological data to assess the use of VP1 sequencing for the early  
77 identification of viruses posing a public health risk. Given that global surveillance and outbreak  
78 responses rely on VP1 sequencing, we need a better understanding of how informative VP1  
79 diversity is for characterizing risk of reversion to virulence and transmission of virulent viruses.

80 Here, we followed the evolution and transmission of the three OPV serotypes during a  
81 prospective study of OPV shedding following a vaccine campaign in semi-rural communities in  
82 Veracruz State, Mexico<sup>13</sup>. We sequenced OPV VP1 genes from stool sampled from vaccinated  
83 children, their household contacts, and community members in unvaccinated households for 10  
84 weeks following the vaccination campaign. This provides a rare opportunity to observe the early  
85 evolution and transmission of the three OPV serotypes following vaccination campaigns and to  
86 evaluate the current use of VP1 sequencing as an epidemiological tool.

87

## 88 **Methods**

89

### 90 *Prospective sampling*

91 We conducted a prospective study of OPV shedding and transmission following a  
92 trivalent OPV vaccination campaign during Mexico's February 2015 National Health Week in

93 three semi-rural populations in Orizaba, Veracruz State<sup>13</sup> (Fig. 2). Wild poliovirus has not been  
94 reported since 1994 in Mexico. Mexico's national vaccine program has included routine IPV as  
95 well as two annual OPV vaccination campaigns since 2007 and therefore provides a model for  
96 transmission of OPV in a setting with routine IPV immunization, an epidemiological context  
97 which will increasingly exist as IPV replaces OPV and OPV is only used as a tool for cVDPV or  
98 wild poliovirus outbreak response.

99 We randomized 466 households to the vaccine and no-vaccine arm of our study across  
100 three communities which were assigned to OPV vaccination rates of 10%, 30%, and 70%. In  
101 total, 155 children (8.5% of the population) were vaccinated with trivalent OPV during the  
102 National Health Week. Vaccinated children and their household contacts were followed  
103 prospectively and stool was collected from all members of sampled households 1 day prior to  
104 the National Health Week OPV immunization campaign, and 1, 4, 7, 10, 14, 21, 28, 51, and 71  
105 days following, for a total of 10 samples per person<sup>13</sup>. Study nurses collected immunization  
106 histories and additional demographic and clinical metadata from all study participants.

107 The study was approved by the Stanford University Institutional Review Board (Protocol  
108 #31546), the Comité de Etica, Bioseguridad e Investigación of the Instituto Nacional de Salud  
109 Pública (CI: 1260, No. 1581), and the Instituto Veracruzano para la Formación e Investigación  
110 en Salud (SESVER/IVEFIS//SIS/DIB/0109/02014, classification 15S).

111

### 112 *Sanger sequencing of VP1 gene*

113 We extracted RNA from frozen stool samples and tested samples for OPV with serotype-  
114 specific RT-qPCR<sup>13,14</sup>. We Sanger sequenced the VP1 gene using the Y7 and Q8R primers<sup>15</sup> and

115 generated consensus sequences by aligning forward and reverse sequences to serotype-specific  
116 reference genomes in *Geneious* v7.

117

### 118 *Bioinformatic analysis*

119 We aligned VP1 gene sequences of each OPV serotype to the corresponding Sabin  
120 vaccine sequence (GenBank Accession Numbers: AY184219, AY184220, AY184221) with  
121 MAFFT v.7<sup>16</sup>, with the algorithm recommended for closely related viral sequences  
122 (<https://mafft.cbrc.jp/alignment/software/closelyrelatedviralgenomes.html>), preserving the  
123 alignment length of the reference sequence. We used the default alignment strategy and a  
124 nucleotide sequence scoring matrix of 1PAM /  $\kappa=2$ , recommended for closely related DNA  
125 sequences.

126 We quantified pairwise distances between samples with the R package *ape* (pairwise  
127 deletion = TRUE)<sup>17</sup>. For household contacts and community members who were not vaccinated  
128 with OPV, we measured time since vaccination as the time since vaccination of the household  
129 member or the earliest vaccination given in the community, respectively. We visualized  
130 haplotype networks built from minimum spanning trees with the R package *pegas*<sup>18</sup>.

131

### 132 *Data availability.*

133 The full-length VP1 sequences used in our study are publicly available on GenBank  
134 (Submission 2683280, 2683353, and 2683683). The reference sequences used for sequence  
135 alignment are publicly available on GenBank (AY184219, AY184220, AY184221). Multiple  
136 sequence alignments and metadata to reproduce figures and analyses are publicly available on  
137 GitHub (<https://github.com/ksw9/opv-consensus>).

138

139

140 *Code availability.*

141 Code for analysis and figures is publicly available on GitHub

142 (<https://github.com/ksw9/opv-consensus>).

143

144 *Global poliovirus data.*

145 We accessed World Health Organization poliovirus case data from the WHO extranet

146 (<https://extranet.who.int/polio/public/CaseCount.aspx>), including both global and country-level

147 reported cases from 2000-2022.

148

## 149 **Results**

150

### 151 **Sample collection**

152 During a prospective study of OPV shedding following a National Health Week

153 vaccination campaign in Veracruz State, Mexico, we collected 15,331 stool samples over 10

154 weeks following vaccination. From these samples, 551 samples were positive for at least one

155 OPV serotype, including 267 OPV-1, 402 OPV-2, and 317 OPV-3 positive samples. We

156 sequenced 358 high quality VP1 genes from 174 individuals, including 18.4% (49/267) positive

157 OPV-1 samples, 33.8% (136/402) positive OPV-2 samples, and 54.5% (173/317) OPV-3

158 samples. Sequence data was available for 99 vaccinated children, 41 household contacts of

159 vaccinated children, 31 members of the community outside of vaccinated households, and 3

160 individuals without known vaccination status. For 84 infections (unique individuals and

161 serotypes), longitudinal samples were available at 2-5 sampling points. The prospective study  
162 was conducted in three semi-rural villages; samples include 106 individuals from Capoluca,  
163 where 70% of children less than five in participating households were vaccinated; 49 from  
164 Campo Grande, where 30% were vaccinated; and 19 individuals from Tuxpanguillo, where 10%  
165 were vaccinated.

166

### 167 **Genetic instability of OPV**

168 We observed a rapid rise of VP1 diversity in all three serotypes over weeks following  
169 OPV vaccination. The most common haplotype for both OPV-1 and OPV-2 in each sampling  
170 location represents the Sabin vaccine strain (Fig. 3), with a star-like pattern in the haplotype  
171 networks, where most haplotypes are directly connected to the Sabin haplotype. Outside of the  
172 dominant haplotype, most haplotypes are represented by a single sample.

173 In contrast, for OPV-3, the dominant haplotype differs by a single nucleotide  
174 polymorphism (SNP) from the vaccine strain, a previously described attenuating site, C2493U  
175 (Fig. 3). Again, there is a star-like pattern of OPV-3 diversity, with many branches stemming  
176 directly from the dominant haplotype. As with OPV-2 and OPV-3, most haplotypes outside the  
177 dominant haplotype are represented by a single sample.

178

### 179 **Clock-like early evolution of OPV following vaccination campaigns**

180 The Global Polio Eradication Initiative (GPEI) defines VDPVs by their divergence from  
181 the Sabin vaccine in the VP1 gene (>1% divergent or  $\geq 10$  substitutions for serotypes 1 and 3,  
182 0.6% divergent or  $\geq 6$  substitutions for serotype 2)<sup>6</sup>. The majority, 99% (337/340), of all samples  
183 sequenced following vaccination fell under the thresholds for a VDPV. However, two samples



184 from vaccinated children, collected 4 days after vaccination met the definition of a VDPV2 (VP1  
185 genetic distance 14 and 8 SNPs from Sabin 2) and one sample from a household contact sampled  
186 30 days following vaccination met the definition of a VDPV1 (10 SNPs distant from Sabin 1)  
187 (Fig. 4).

188 We then examined if the early evolution of OPV follows a molecular clock and, therefore, if  
189 OPV divergence from Sabin vaccine strains could be used to estimate the duration of viral  
190 circulation. Genetic divergence of OPV-1 was significantly associated with time following  
191 vaccination in both vaccinated children ( $p < 0.001$ , Pearson's  $r = 0.42$ ) and non-vaccinated  
192 individuals ( $p < 0.001$ , Pearson's  $r = 0.90$ ) (Fig. 4). When considering all samples together, the  
193 observed mutations in OPV-1 corresponded to a VP1 gene evolutionary rate of  $1.2 \times 10^{-4}$   
194 substitutions per site per day. Genetic divergence of OPV-2 was not significantly associated with  
195 time following vaccination in vaccinated children ( $p=0.3$ , Pearson's  $r = -0.11$ ) and was positively  
196 correlated with time among non-vaccinated individuals, though not significantly so ( $p =0.07$ ,  
197 Pearson's  $r = 0.31$ ) (Fig. 4). OPV-3 divergence was positively associated with time following  
198 vaccination for non-vaccinated individuals ( $p = 0.007$ , Pearson's  $r = 0.48$ ), but not vaccinated  
199 children ( $p = 0.26$ , Pearson's  $r = -0.1$ )

200 We reasoned that mutations at known attenuating positions may be under strong selection  
201 and could affect an estimate of molecular clock. However, excluding the known attenuating sites  
202 in the VP1 gene did not substantially change observed associations between genetic divergence  
203 and time (Fig. S1).

204

205 **Moderate signal of recent transmission in OPV VP1 gene sequence diversity**

206 VP1 genetic diversity is also used by the GPEI to determine if a VDPV is genetically  
207 linked to previously collected environmental or clinical samples, which makes it a cVDPV, and  
208 whether viruses are linked to a previously identified cVDPV emergence or constitute a new  
209 emergence.

210 To test whether VP1 sequence divergence is genetically structured and could provide  
211 evidence of  
212 recent transmission, as is done with several pathogens, we compared pairwise genetic distances  
213 across samples. As expected with the relatively short duration of sampling following vaccination  
214 campaigns, 28.9% (694/2400) of OPV-1; 40.6% (67,16/16,504) of OPV-2; and 42.0%  
215 (12,498/29,974) of OPV-3 VP1 pairs of sequences were identical. Mean pairwise distance was  
216 2.4 SNPs for OPV-1, 1.5 SNPs for OPV-2, and 1.4 SNPs for OPV-3 (Fig. 5).

217 In a general linear model, pairwise genetic distance between VP1 samples was elevated  
218 for individuals from the same household (aOR: 1.29; 95% CI: 1.11-1.50), from the same  
219 community (aOR: 1.49; 95% CI: 1.34-1.64), and from different communities (aOR: 1.63; 95%  
220 CI: 1.48-1.80), compared to samples collected from an individual. As expected, longitudinal  
221 samples from an individual were mostly conserved over the sampling time. Genetic structure  
222 varied across serotypes: compared to OPV-1, we observed decreased pairwise genetic distances  
223 for both OPV-2 (aOR: 0.64; 95% CI: 0.62-0.65) and OPV-3 (aOR: 0.58; 95% CI: 0.57-0.60).

224

### 225 **Rapid loss of OPV attenuating mutations in the VP1 gene following vaccination campaigns**

226 We then examined known mutations at key attenuating sites in the vaccine virus,  
227 associated with the reversion of vaccine viruses to virulence. Of three known virulence  
228 attenuating substitutions in the OPV-1 VP1 gene, 16% (8/49) of samples had a A2749G (Sabin

229 to virulent wildtype) mutation, including 4 vaccinated children and 2 household contacts. The  
230 mutation first appeared 14 days following vaccination in a vaccinated child and contact in one  
231 house and in another vaccinated child independently and rose in frequency, although there were  
232 limited OPV-1 samples available 4+ weeks after vaccination. It was observed in stool up to 52  
233 days after the vaccination campaign. A single sample shed by a vaccinated child harbored a  
234 A2795G substitution, and no U2879C attenuating mutations occurred (Fig. 6).

235         Among OPV-2 samples, the known VP1 reversion mutation, U2909C/A, occurred in  
236 4.4% (6/136) of samples, in four vaccinated children. The substitution was first observed 7 to 14  
237 days after vaccination; two children shed OPV-2 carrying this reversion mutation on multiple  
238 days. The mutation was observed in stool up to 21 days following the vaccination campaign,  
239 though again, there were limited OPV-2 samples available 4+ weeks after vaccination. No  
240 individuals had mutations present at the adjacent site 2908, also associated with reversion<sup>19</sup>.

241         Among OPV-3 samples, the majority, 91% (157/173), had a C2493A/G/U eversion  
242 substitution and an additional 11 samples had a mixed allele or no allele call at that site, possibly  
243 evidence of mixed infection. Samples with a C2493A/G/U mutation included 95% (89 of 94) of  
244 individuals with OPV-3 sequences available, including 63 vaccinated children, 18 household  
245 members, and 8 individuals outside of vaccinated households. The mutation first appeared one  
246 day following the vaccination in vaccinated children, household members, and individuals  
247 outside vaccinated households and it was observed in stool up to 72 days after the vaccination  
248 campaign from a vaccinated child and 70 and 54 days from virus shed in a household member  
249 and community member, respectively.

250

251 **Discussion**

252 Global poliovirus surveillance uses molecular epidemiology to directly guide outbreak  
253 responses. However, the informativeness of the routinely sequenced marker gene, VP1, in the  
254 early identification of VDPVs posing a public health risk has not been evaluated in a controlled  
255 setting.

256 Here, we leveraged OPV sampled for 10 weeks following an immunization campaign in a  
257 population previously vaccinated with IPV to assess the epidemiological information within VP1  
258 samples. We found that all three OPV serotypes are genetically unstable in the weeks following  
259 vaccination campaigns, consistent with previous reports. We identified evidence of clocklike  
260 VP1 evolution across serotypes (though this signal differed by vaccine status) and significant  
261 genetic structure. However, we found evidence of frequent reversion substitutions among viruses  
262 classified as Sabin-like, suggesting that current definitions of cVDPVs may exclude circulating  
263 viruses that have regained key virulence-associated mutations and which may pose a public  
264 health risk.

265

#### 266 *VP1 informativeness*

267 Polioviruses are among the fastest evolving RNA viruses and we observed that the rapid  
268 generation of genetic diversity in vaccinated children and their household and community  
269 contacts contains epidemiological information. Early evolution of OPV is largely clocklike, with  
270 variation in mutation rate across serotypes. The lack of a signal of clocklike evolution of OPV-2  
271 and OPV-3 in vaccinated children likely reflects the shorter sampling period for vaccinated  
272 children; unvaccinated household and community contacts were infected later in the study by  
273 vaccine-derived viruses which had already passed through at least one host.

274 Our estimate of the OPV-1 VP1 substitution rate of  $1.2 \times 10^{-4}$  substitutions/site/day  
275 (including all samples) was similar to previous estimates of OPV-1 evolution  $0.83 \times 10^{-4}$   
276 substitutions/site/day<sup>20</sup> (estimated from three years of surveillance for acute flaccid paralysis)  
277 and faster than the estimate of the molecular clock for wild poliovirus type 1 evolution of  $0.28 \times$   
278  $10^{-4}$  substitutions/site/day, estimated from a set of 31 viruses sampled over ten years<sup>10</sup>. The  
279 differences in substitution rate may reflect the different sampling durations, as shorter sampling  
280 durations often yield higher pathogen substitution rates estimates, likely because purifying  
281 selection has not yet removed transient deleterious mutations are still present prior to the effect  
282 of purifying selection<sup>21,22</sup>. It is also likely that Sabin vaccine viruses evolve more rapidly than  
283 wildtype viruses.

284 We observe moderate genetic structure in VP1 sequences, with increasing genetic  
285 divergence between samples from different communities compared to that sampled within the  
286 same community, household, or longitudinally within an individual. Yet VP1 divergence is not  
287 sufficient to make predictions about transmission linkage. Whole genome sequences and  
288 additional epidemiological information about timing of infection and contacts could improve  
289 inference of transmission networks.

290

### 291 *Reversion to virulence*

292 The rapid reversion to virulence of Sabin vaccines is well documented<sup>23-25</sup>. While each  
293 serotype has key attenuating mutations in the IRES, additional mutations along the genome,  
294 including in the VP1 gene, stabilize the attenuated phenotype<sup>26</sup>. In OPV-2, a predictable  
295 evolutionary route towards virulence includes gatekeeper mutations including an IRES mutation,

296 followed by a VP1 gene mutation, and a reversion in the 5' UTR, followed by a wave of  
297 recombination events<sup>27,28</sup>.

298 We found a high frequency of attenuating substitutions in VP1, with substitutions  
299 appearing early after vaccination. The higher frequency of OPV-2 and OPV-3 reversion  
300 mutations we observed could reflect the greater observed genetic stability of OPV-1, which  
301 differs from the virulent wild-type progenitor virus by 59 substitutions, compared to OPV-2 and  
302 OPV-3 which are more closely related to the virulent ancestor<sup>29</sup>. Our group previously found that  
303 97% of OPV-3 recipients shed viruses that had a site 472 reversion mutation within two weeks  
304 following vaccination<sup>30,31</sup>. The instability of OPV-3 has epidemiological consequences: OPV-3  
305 causes the majority of vaccine-associated paralytic poliomyelitis (VAPP), paralysis attributable  
306 to the vaccine itself, followed by OPV-2 and then OPV-1<sup>3</sup>.

307 However, previous studies have reported heterogeneity at the OPV-3 C2493U attenuating  
308 mutation in vaccine stocks<sup>32</sup>. We did not have access to vaccine stocks and therefore cannot  
309 determine if the near-fixation of an attenuating mutation we observe was due to heterogeneity in  
310 the vaccine or *de novo* evolution in vaccinated children and subsequent onwards transmission.

311

### 312 *Identifying viruses of public health concern*

313 Although the majority of OPV samples in our study collected were defined as Sabin-like  
314 viruses, rather than VDPVs, based on sequence divergence, many of the Sabin-like viruses had  
315 rapidly lost attenuating mutations at previously described positions. While VP1 sequence  
316 divergence may be useful in estimating duration of circulation or predicting transmission cluster,  
317 OPV circulating for short periods, that does not yet meet GPEI definitions for a cVDPV, can be  
318 virulent and can pose a public health risk in populations without prior immunity. For example,

319 Sabin-like OPV-2 viruses, which were 3 SNPs distant to the Sabin virus VP1 sequence, were  
320 previously found to have caused a cluster of acute flaccid paralysis cases in an orphanage in  
321 Altai Region of Russia<sup>33</sup>. All outbreak genomes shared 15 substitutions compared to the Sabin  
322 virus, including the loss of attenuation mutations A481G and U2909C.



323         The global increase of cVDPV2 outbreaks has increased dramatically since 2016, when  
324 Sabin 2 was removed from the trivalent poliovirus vaccine<sup>5</sup>. Our results are consistent with  
325 previous work on the genetic instability of OPV and rapid reversion to virulence. Our finding  
326 that current definitions of cVDPVs may exclude virulent Sabin-like viruses underscores the  
327 urgency in heightened surveillance during and following vaccination campaigns.

328

#### 329 **Funding Information**

330 This project was funded by the National Institutes of Health 5R21AI148810 to YM. KSW was  
331 funded by a Thrasher Early Career Award and a Stanford Child Health Research Institute  
332 postdoctoral fellowship.


333 **Figure 1. The increasing global burden of vaccine-derived poliovirus.** (a) Confirmed cases of  
 334 paralytic polio reported to the World Health Organization from 2000-2022. Color indicates source:  
 335 circulating vaccine derived poliovirus (cVDPV) and wild poliovirus cases. (b) Map of countries reporting  
 336 cVDPV cases in from 2020-2022; fill indicates number of cVDPV cases identified. Data from the World  
 337 Health Organization.  
 338



339




340 **Figure 2. Prospective study of OPV shedding among vaccinated children, household members, and**  
341 **community members following a vaccination campaign.** (a) Map of Mexico with Veracruz State  
342 highlighted and Orizaba city, where the study took place, indicated with a red point. (b) We conducted a  
343 prospective observational study of OPV viral shedding following a vaccination campaign. 155 children  
344 were enrolled and vaccinated with trivalent OPV. Stool was collected from vaccinated children,  
345 unvaccinated household members, and community members in unvaccinated households. We extracted  
346 RNA from stool samples, tested samples with OPV serotype-specific RT-PCR, and Sanger sequenced  
347 positive samples.




348  
349

350 **Figure 3. Limited overall genetic diversity in sampled OPV viral capsid protein 1 (VP1) gene**  
 351 **following vaccination campaigns.** For each OPV serotype and sampling site, haplotype networks of  
 352 OPV VP1 representing sampled genetic diversity. Nodes indicate identical haplotypes (VP1 consensus  
 353 sequences) and node size indicates the number of samples sharing a haplotype. Points on edges between  
 354 nodes indicate the SNP distance between haplotypes and node colors indicate individual's vaccination  
 355 status. Labels indicate OPV serotype and study site. Site C, Capoluca, had 70% vaccination coverage of  
 356 eligible children; site CG, Campo Grande: 30%; site T, Tuxpanguillo: 10%. One sample with a distant  
 357 haplotype (>14 SNPs distant to the Sabin vaccine) was removed from OPV-2 site C, to aid visualization.




359 **Figure 4. Measurable evolution in the OPV VP1 gene following vaccination campaigns.** Genetic  
 360 distance of the OPV VP1 gene to the Sabin vaccine strain versus time from vaccination for vaccinated  
 361 children (blue) and not vaccinated study participants, including household contacts and unvaccinated  
 362 community members (red), for each OPV serotype (a-c). Black lines and grey shading of a linear model  
 363 for distance to the Sabin strain. Days following vaccination is measured as days from first vaccination  
 364 (for vaccinated children), day from first household vaccination (for non-vaccinated household members),  
 365 and days from first community vaccination (for non-vaccinated community members). Red dashed lines  
 366 indicate the genetic distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for  
 367 serotypes 1 and 3 and 6 SNPs distant for serotype 2.  
 368



369


370 **Figure 5. Moderate genetic structure of OPV VP1 gene from samples shed two months following**  
 371 **vaccination campaigns.** The proportion of pairs of OPV VP1 sequences within a given, binned pairwise  
 372 genetic distance for samples collected longitudinally from the same individual, from the same household,  
 373 the same community, or outside the community. Facets indicate OPV serotype.



374  
375

376 **Figure 6. Loss of OPV attenuating mutations following vaccination.** For each serotype, points indicate  
 377 the revertant proportion, the proportion of samples with a mutation at a key attenuating position in OPV  
 378 in the weeks following vaccination. Bars indicate the total number of sequences available for that  
 379 sampling week. Each serotype has unique attenuating sites.

380




381  
382

383 **Supplementary Figures**

384

385 **Figure S1. Measurable evolution in the OPV VP1 gene following vaccination campaigns when**  
 386 **excluding attenuating mutations.** Genetic distance of the OPV VP1 gene to the Sabin vaccine strain  
 387 versus time from vaccination for vaccinated children (blue) and not vaccinated study participants (red),  
 388 for each OPV serotype (a-c). Black lines and grey shading of a linear model for distance to the Sabin  
 389 strain. Days following vaccination is measured as days from first vaccination (for vaccinated children),  
 390 day from first household vaccination (for non-vaccinated household members), and days from first  
 391 community vaccination (for non-vaccinated community members). Red dashed lines indicate the genetic  
 392 distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for serotypes 1 and 3 and 6  
 393 SNPs distant for serotype 2.



394

- 395 1. Khan, F. et al. Progress Toward Polio Eradication — Worldwide, January 2016–March 2018.  
396 *Morb. Mortal. Wkly. Rep.* **67**, 524 (2018).
- 397 2. Jorba, J. et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–  
398 June 2019. *Morb. Mortal. Wkly. Rep.* **68**, 1024 (2019).
- 399 3. Platt, L. R., Estivariz, C. F. & Sutter, R. W. Vaccine-Associated Paralytic Poliomyelitis: A Review  
400 of the Epidemiology and Estimation of the Global Burden. *J. Infect. Dis.* **210**, S380–S389 (2014).
- 401 4. Chumakov, K. M., Brechot, C., Gallo, R. C. & Plotkin, S. Choosing the Right Path toward Polio  
402 Eradication. *NEJM* **388**, 577–579 (2023).
- 403 5. Macklin, G. R. et al. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016  
404 and 2020. *Vaccine* (2022) doi:10.1016/j.vaccine.2022.08.008.
- 405 6. Global Polio Eradication Initiative. *Classification and reporting of vaccine-derived polioviruses*  
406 *(VDPV) - GPEI guidelines*. [http://polioeradication.org/wp-content/uploads/2016/09/Reporting-](http://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf)  
407 [and-Classification-of-VDPVs\\_Aug2016\\_EN.pdf](http://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf) (2016).
- 408 7. Jorgensen, D., Pons-Salort, M., Shaw, A. G. & Grassly, N. C. The role of genetic sequencing and  
409 analysis in the polio eradication programme. *Virus Evol.* **6**, (2020).
- 410 8. Jorba, J. Phylogenetic analysis of poliovirus sequences. *Methods Mol. Biol.* **1387**, 227–237 (2016).
- 411 9. Burns, C. C. et al. Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses  
412 during a Large Outbreak in Northern Nigeria. *J. Virol.* **87**, 4907–4922 (2013).
- 413 10. Jorba, J., Campagnoli, R., De, L. & Kew, O. Calibration of Multiple Poliovirus Molecular Clocks  
414 Covering an Extended Evolutionary Range. *J. Virol.* **82**, 4429–4440 (2008).
- 415 11. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong  
416 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* **29**, 32-43.e4 (2021).
- 417 12. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19  
418 (2017).
- 419 13. Sarnquist, C. et al. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After  
420 Cessation of Routine Oral Poliovirus Vaccine Immunization. *Clin. Infect. Dis.* **67**, S115–S120  
421 (2018).
- 422 14. Troy, S. B. et al. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and  
423 reversion in stool and sewage samples after a mexican national immunization day. *J. Clin.*  
424 *Microbiol.* **49**, 1777–83 (2011).
- 425 15. Kilpatrick, D. R. et al. Poliovirus serotype-specific VP1 sequencing primers. *J. Virol. Methods*  
426 **174**, 128–130 (2011).
- 427 16. Nakamura, T., Yamada, K. D., Tomii, K. & Katoh, K. Parallelization of MAFFT for large-scale  
428 multiple sequence alignments. *Bioinformatics* **34**, 2490–2492 (2018).
- 429 17. Paradis, E. & Schliep, K. Ape 5.0: An environment for modern phylogenetics and evolutionary  
430 analyses in R. *Bioinformatics* **35**, 526–528 (2019).
- 431 18. Paradis, E. pegas: an {R} package for population genetics with an integrated--modular approach.  
432 *Bioinformatics* **26**, 419–420 (2010).
- 433 19. Wahid, R. et al. Genetic and phenotypic stability of poliovirus shed from infants who received  
434 novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.  
435 *The Lancet Microbe* **3**, e912–e921 (2022).
- 436 20. Famulare, M. et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-  
437 Like Poliovirus Isolates in Nigeria. *J. Virol.* **90**, 317–331 (2016).
- 438 21. Duchêne, S., Holmes, E. C. & Ho, S. Y. W. Analyses of evolutionary dynamics in viruses are  
439 hindered by a time-dependent bias in rate estimates. *Proc. R. Soc. B Biol. Sci.* **281**, (2014).
- 440 22. Holmes, E. C. Molecular Clocks and the Puzzle of RNA Virus Origins. *J. Virol.* **77**, 3893 (2003).
- 441 23. Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. VACCINE-  
442 DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO  
443 ERADICATION. *Annu. Rev. Microbiol.* **59**, 587–635 (2005).
- 444 24. Duintjer Tebbens, R. J. et al. Oral poliovirus vaccine evolution and insights relevant to modeling  
445 the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal.* **33**, 680–702 (2013).

- 446 25. Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-derived polioviruses. *J. Infect.*  
447 *Dis.* **210**, S283–S293 (2014).
- 448 26. Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-  
449 Derived Polioviruses and the Endgame Strategy for Global Polio Eradication \*. (2005)  
450 doi:10.1146/annurev.micro.58.030603.123625.
- 451 27. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19  
452 (2017).
- 453 28. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong  
454 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* **29**, 32-43.e4 (2021).
- 455 29. Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-  
456 derived polioviruses and the endgame strategy for global polio eradication. *Annual Review of*  
457 *Microbiology* vol. 59 587–635 (2005).
- 458 30. Gnanashanmugam, D. et al. Shedding and Reversion of Oral Polio Vaccine Type 3 in Mexican  
459 Vaccinees: Comparison of Mutant Analysis by PCR and Enzyme Cleavage to a Real-Time PCR  
460 Assay. *J. Clin. Microbiol.* **45**, 2419 (2007).
- 461 31. Martinez, C. V. et al. Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-  
462 cytosine point mutation after administration of oral poliovirus vaccine. *J. Infect. Dis.* **190**, 409–  
463 416 (2004).
- 464 32. Neverov, A. & Chumakov, K. Massively parallel sequencing for monitoring genetic consistency  
465 and quality control of live viral vaccines. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 20063–20068 (2010).
- 466 33. Korotkova, E. A. et al. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly  
467 Diverged Sabin 2 Vaccine Poliovirus. *J. Virol.* **90**, 5978 (2016).
- 468